Ticker

Abpro Holdings Inc. (NASDAQ: ABP - Get Free Report) was the recipient of a significant increase in short interest during the month of January. As of January 30th, there was short interest totaling 18,253 shares, an increase of 271.4% from the January 15th total of 4,914 shares. Currently, 0.8% of the shares of the company are

BURLINGTON, Mass., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq: ABP), a clinical-stage biotechnology company developing next-generation antibody therapeutics for solid tumors, today announced that its lead multispecific antibody oncology program, ABP-102 / CT-P72, was featured in a presentation by its global collaboration partner, Celltrion, at the 2026 J.P.

FDA clearance enables initiation of Abpro's first clinical-stage solid tumor program Clinical trial anticipated to commence in the first half of 2026 through Abpro's global collaboration with Celltrion BURLINGTON, Mass. and INCHEON, South Korea, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq: ABP), a biotechnology company developing next-generation antibody therapeutics for solid tumors, today…

Shares of Abpro Holdings Inc. (NASDAQ: ABP - Get Free Report) were up 0.2% during trading on Thursday. The stock traded as high as $4.80 and last traded at $4.79. Approximately 12,770 shares changed hands during trading, a decline of 47% from the average daily volume of 24,173 shares. The stock had previously closed at

IND submitted for ABP-102/CT-P72, a HER2 × CD3 T cell engager, with preclinical studies demonstrating enhanced HER2-high tumor selectivity and a favorable safety profile ABP-102/CT-P72 represents Abpro's first IND submission for a phase 1 trial in a solid tumor indication, and is being co-developed by Abpro and Celltrion, Inc. BURLINGTON, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq: ABP,…